Therefore, the present consensus panel was established with the rationale of identifying the clinical, pathological, morphological, and genetic factors potentially related to a high risk of recurrence, in order to better inform treatment decisions in patients with HR+/HER2− early BC (eBC). The gene discussed is HR; the disease is breast cancer.